| Literature DB >> 34056682 |
Koichi Yamaguchi1, Aya Yamaguchi2, Miki Itai3, Yuji Onuki2, Yuki Shin2, Shogo Uno2, Chiharu Hanazato2, Kohei Taguchi3, Kazue Umetsu3, Masaki Aikawa2, Shunichi Kouno2, Masao Takemura3, Kenichiro Hara2, Shinsuke Motegi4, Mayuko Tsukida4, Fumie Ota4, Yoshito Tsukada4, Mitsuru Motegi3, Masao Nakasatomi5, Toru Sakairi5, Hidekazu Ikeuchi5, Yoriaki Kaneko5, Keiju Hiromura5, Toshitaka Maeno2.
Abstract
Anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) occurs in elderly people, and patients with anti-myeloperoxidase autoantibodies (MPO-ANCA)-positive AAV are often complicated with interstitial lung disease (ILD). This study aimed to evaluate the age-related clinical features of elderly patients with MPO-ANCA-positive AAV-ILD. This study retrospectively investigated 63 patients with MPO-ANCA-positive AAV-ILD, all of whom were 65 years or older at diagnosis. Clinical characteristics, causes of death and survival rates among three groups stratified by age (65-74 years, n = 29; 75-79 years, n = 18; over 80 years, n = 16) were compared. This study also examined the association with severe infections in these patients. Among the three age groups, there were significant differences in sex (P = 0.032), serum Krebs von den Lungen-6 (P < 0.01), and total ground-glass opacity score (P = 0.011). The causes of death were mainly severe infections and complications of ILD. Kaplan-Meier curve analysis showed a significantly lower 5-year survival rate in the oldest group (P < 0.01). Regarding severe infections in these patients, the 5-year cumulative incidence of severe infections was higher in the patients receiving steroid pulse therapy (P = 0.034). The clinical characteristics of MPO-ANCA-positive AAV-ILD differ with age in elderly patients, with age being an important poor prognostic factor in these patients. The administration of steroid pulse therapy is a significant risk factor of severe infection in MPO-ANCA-positive elderly patients with AAV-ILD.Entities:
Keywords: Age; Anti-neutrophil cytoplasmic antibody; Elderly; Interstitial lung disease
Mesh:
Substances:
Year: 2021 PMID: 34056682 DOI: 10.1007/s00296-021-04891-7
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631